Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.

The oncologist - 1 Jun 2020

Xu Xian, Yang Yang, Liu Xiaoyan, Cao Na, Zhang Peng, Zhao Songhui, Chen Donglin, Li Li, He Yong, Dong Xiaowei, Wang Kai, Lin Hanqing, Mao Naiquan, Liu Lingxiang

Abstract excerpt

BACKGROUND: Abnormalities in the KEPA1-NRF2 pathway have a role in cancer progression, metastasis, and resistance to chemo- and radiotherapies. Persistent activation of NRF2 associates with poor prognosis across different cancer types. However, the beneficial therapeutic strategy to harness this pathway in cancer remains unclear. This study aimed to investigate the clinical outcome with immunotherapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kelch-Like ECH-Associated Protein 1

Share to Lung Neoplasms

Share to Mutation

Share to NF-E2-Related Factor 2

Source

Open in PubMed Open full text

Identifiers

PMID: 32272498
DOI: 10.1634/theoncologist.2019-0885
PMCID: PMC7288635

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.PMID 32272498Read ↗

KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.Semantic proximity Read ↗

Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.Semantic proximity Read ↗

Integrative omics analysis identifies subtypes with therapeutic implications in lung adenocarcinoma harboring KEAP1/NFE2L2Semantic proximity Read ↗

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.Semantic proximity Read ↗

Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond.Semantic proximity Read ↗

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activationSemantic proximity Read ↗

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).Semantic proximity Read ↗

Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.Semantic proximity Read ↗

Transcriptional phenocopies of deleterious<i>KEAP1</i>mutations dictate survival outcomes in lung cancer treated with immunotherapySemantic proximity Read ↗

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.